Vaxcyte
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: San Carlos, California, United States, North America
Region: California
Country: US
Continent: North America
About
Vaxcyte is a biotechnology company focused on creating next-generation vaccines to prevent bacterial infections worldwide. The company develops vaccine candidates, including pneumococcal conjugate vaccines, with a platform that re-engineers how vaccines are made using advanced chemistry and synthetic techniques. It emphasizes high-fidelity vaccines engineered to broaden protection against invasive pneumococcal disease and other bacterial pathogens. Vaxcyte highlights U.S. manufacturing expansion in North Carolina as part of its strategy to strengthen domestic vaccine production.
Vaxcyte is a biotechnology company developing next-generation vaccines to prevent bacterial infections. The firm utilizes a proprietary site-specific, carrier-sparing platform to engineer high-fidelity vaccines, such as those targeting pneumococcal disease and Group A Streptococcus. Its primary customers are public health entities and healthcare systems seeking improved protection against invasive
Vaxcyte, Inc.
2013
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
4200000000
1m-10m
ipo
NASDAQ:PCVX
nasdaq
Investors
Founders
Ash Khanna
Grant E. Pickering
Jeff Fairman
Leadership
Grant E. Pickering — Co-Founder, CEO & Director
Paul W. Sauer — Senior Vice President, Process Development & Manufacturing
Michael Mullette — Chief Commercial Officer
Andrew Guggenhime — President and Chief Financial Officer
Whitney Jones — Chief People Officer
Jeff Fairman — Founder & Vice President, Research
Agustin Mohedas — board_observer
Technology Stack
Products
VAX-31: A 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease in adults and infants by covering a broad spectrum of serotypes.
VAX-24: A 24-valent pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease in infants by covering more serotypes than existing infant PCVs.
VAX-A1: A preclinical conjugate vaccine candidate targeting Group A Streptococcus infections to provide broad and durable protection.
VAX-PG: A therapeutic vaccine candidate targeting the pathogen responsible for periodontitis to prevent oral bone loss and related complications.
VAX-GI: A preclinical vaccine candidate designed to prevent Shigella infections, which cause dysentery and shigellosis, by eliciting broad immune protection.
Funding rounds
Post Ipo Equity · $632.5M · (2026-01-29)
Post Ipo Equity · $1.5B · (2024-09-04)
Post Ipo Equity · $862.5M · (2024-01-30)